Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 24Colorectal Neoplasms 16Small Cell Lung Carcinoma 6Stomach Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Biliary Tract Neoplasms 4Sarcoma, Ewing 3Rhabdomyosarcoma 3Recurrence 3Rectal Neoplasms 3Osteosarcoma 3Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Cholangiocarcinoma 2Wilms Tumor 1Weight Loss 1Triple Negative Breast Neoplasms 1Somatostatinoma 1Solid Tumor Cancer 1Solid Tumor 1Small Cell Lung Cancer Extensive Stage 1Small Bowel Adenocarcinoma 1Sarcoma 1Rhabdoid Tumor 1

Interventions

pembrolizumab 2Radiotherapy 2Etoposide 2Carboplatin 2sintilimab 1irinotecan sucrosofate 1durvalumab 1atezolizumab 1apatinib 1anlotinib 1amrubicin 1Platinum 1Paclitaxel 1Observation 1NPI 2358 1Immunotherapy 1Immune Checkpoint Inhibitors 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Small Cell Lung Cancer Extensive Stage × irinotecan sucrosofate × Clear all
NCT06739928 2024-12-18

Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

Guangzhou Institute of Respiratory Disease

Phase 2 Recruiting
120 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡